April 24, 2024 Second notice of the Ordinary and Extraordinary Shareholders’ Meeting on May 6, 2024 and appointment of an ad hoc agent
March 20, 2024 Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology
March 14, 2024 Nicox to Hold Webcast on March 18 on its Corporate Pipeline and Financing Perspectives and Key NCX 470 Clinical Data with Presentation by Leading French Glaucoma Key Opinion Leader